ClinicalTrials.gg
CompletedNCT05324137DUBHEUpdated Nov 8, 2024

A Study of CM326 in Patients With Chronic Rhinosinusitis With Nasal Polyps

A Phase 1/2 interventional study of CM326 and Placebo in Chronic Rhinosinusitis With Nasal Polyps, sponsored by Keymed Biosciences Co.Ltd. Completed at 1 site in China. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2024-11-08.

Sponsored by Keymed Biosciences Co.Ltd · Phase 1/2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1/2
Study type
Interventional
Enrollment
88
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 46 studies in Nasal Polyps with a site in China — 17 open to participants now, 24 under way, 7 of them phase 3. Nasal Polyps · China.

Enrollment
23rd of 43
88 · median 90
Started
2022
with 4 others
Phase 1/2
2 of 46
1 open now
Registered
15th of 46
by date
Lead sponsor
4 of 46
Keymed Biosciences Co.Ltd

Among the 46 studies in Nasal Polyps with a site in China, this one is the 23rd largest by enrollment of the 43 interventional ones that give a count, is one of 5 that started in 2022, is one of 2 in phase 1/2, and was the 15th registered.

Nasal Polyps

236 studies on the registry are indexed under Nasal Polyps; 68 are open to participants now.

Browse Nasal Polyps studies →

Open to participants now

17 of the 46 studies in Nasal Polyps with a site in China are open now. Recruiting first, the newest first:

12 more — sign in →

All 17 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 40 Nasal Polyps studies recruiting now, 22 (55%) set no upper age limit and 12 (30%) stop at 75 or younger; 2 take children under 18; 7 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 46 studies in Nasal Polyps with a site in China, or all of them as a file.
02

Study summary

This is a multi-center, randomized, double blind, placebo-controlled, dose escalation study to evaluate the safety, tolerability, PK, PD, immunogenicity and preliminary efficacy of CM326 in patients with chronic rhinosinusitis with nasal polyps.

Read the detailed description

The study consists of 3 periods, a Screening Period, a Treatment Period and a Safety Follow-up Period.

Subjects who meet eligibility criteria will be randomized to receive either CM326 or placebo subcutaneously.

03

Conditions studied

  • Chronic Rhinosinusitis With Nasal Polyps
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Subjects who are capable of understanding the nature of the study and voluntarily signing the ICF.
  • Male or female subjects, aged between 18 and 70 years old (inclusive), with a (BMI) ≥ 19 kg/m2.
  • Diagnosed with Chronic Rhinosinusitis With Nasal Polyps.
  • The total NPS score should be at least 3 points, with at least 1 point in each side of the nasal cavity.
  • Prior treatment with systemic (SCS) within two years before screening, and/or contraindicate to or intolerance to systemic corticosteroids, and/or with prior surgery to nasal polyps 6 months before the screening.
  • Ongoing symptoms for at least 4 weeks before screening:1) Nasal congestion/obstruction; 2) Other symptom, e.g., loss of smell or rhinorrhea.

Exclusion criteria

Exclusion Criteria:

  • Allergic or intolerant to mometasone furoate spray or CM326/placebo.
  • Have used of systemic for inflammatory or diseases within 8 weeks or 5 half-lives prior to randomization.
  • Have initiated leukotriene receptor antagonist therapy within 4 weeks prior to randomization.
  • have received allergen-specific immunotherapy that initiated within 3 months prior to randomization or planned to be initiated during the study period.
  • Have undergone nasal surgery (including nasal polypectomy) within 6 months prior to screening.
  • Have received medium- and short-acting systemic (including oral, intravenous, intramuscular corticosteroids), nasal dripping corticosteroids, traditional Chinese medicine (including systemic and local herbal products preparations) for chronic rhinosinusitis (CRS) within 4 weeks prior to screening, or long-acting systemic corticosteroids.
  • With concomitant asthma (including suspected diagnosis of asthma) will be excluded if they meet the following conditions: predicted of≤ 60%, or acute exacerbation of asthma within 3 months prior to screening requiring SCS or hospitalization (> 24 hours), or using inhaled corticosteroids (ICS) of > 1000 μg fluticasone propionate or others at equivalent doses
  • With antrochoanal polyps.
  • With severe deviation of the nasal septum occludes at least one nostril.
  • With persistent rhinitis medicamentosas.
  • With allergic granulomatous angiitis (Churg-Strauss syndrome), granulomatosis with polyangiitis (Wegener's granulomatosis), Young's syndrome, Kartagener's syndrome or other dyskinetic ciliary syndromes, cystic fibrosis.
  • With acute sinusitis, nasal infection, or upper respiratory tract infection at screening.
  • Have symptoms or whose CT scan suggests allergic fungal sinusitis.
  • With malignant or benign neoplasm of nasal cavities.
  • With other uncontrolled serious diseases or recurrent chronic diseases.
  • Have severe hepatic and renal impairment.
  • Have received within 12 weeks prior to randomization, or during the planned study; or have received inactivated vaccines (e.g., novel coronavirus vaccines) within 30 days prior to randomization.
  • With known or suspected immunosuppression, including, but not limited to, the history of invasive opportunistic infections.
  • Subjects who are pregnant or planning to become pregnant, or breastfeeding during the study.
  • With a history of large alcohol consumption or a history of drug abuse within 3 months prior to screening.
  • With other medical or non-medical conditions that are not suitable for participation in the study in the opinion of the investigator.
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

05

Study design

Phase
Phase 1 / Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Sequential assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
88 participants (actual)

Study arms

  • Experimental
    Group 1: 55mg Q2W

    CM326 55 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Drug: CM326 · Other: Placebo

  • Experimental
    Group 2: 110mg Q2W

    CM326 110 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Drug: CM326 · Other: Placebo

  • Experimental
    Group 3: 220mg Q2W

    CM326 220 mg or matched placebo, every 2 weeks, subcutaneous (SC)

    Drug: CM326 · Other: Placebo

  • Experimental
    Group 4: 220mg Q4W

    CM326 220mg or matched placebo, every 4 weeks, subcutaneous (SC)

    Drug: CM326 · Other: Placebo

Interventions

  • DrugCM326

    CM326 injection

  • OtherPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Incidence of AEs, including any abnormal physical examinations, abnormal vital signs, abnormal ECG, and abnormal lab testing.

    Time frame: up to Week 64

  2. Changes from baseline of nasal polyp score (NPS) in eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP) at week 16.

    NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: at week 16

Secondary outcomes

  1. PK: Concentration of CM326 in plasma

    Concentration of CM326 in plasma

    Time frame: up to Week 64

  2. Immunogenicity: anti-drug antibody (ADA)

    Occurrence of positive anti-drug antibody (ADA)

    Time frame: up to Week 64

  3. PD: Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration.

    Changes from baseline in serum thymus activation regulation chemokine (TARC) concentration after CM326 administration.

    Time frame: up to Week 64

  4. PD: Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration.

    Changes from baseline in serum total immunoglobulin E (IgE) concentration after CM326 administration.

    Time frame: up to Week 64

  5. PD: Changes from baseline in plasma interleukin-5 (IL-5) after CM326 administration

    Changes from baseline in plasma interleukin-5 (IL-5) after CM326 administration

    Time frame: up to Week 64

  6. PD: Changes from baseline in plasma interleukin-13 (IL-13) after CM326 administration

    Changes from baseline in plasma interleukin-13 (IL-13) after CM326 administration

    Time frame: up to Week 64

  7. PD: Changes from baseline in serum periostin after CM326 administration

    Changes from baseline in serum periostin after CM326 administration

    Time frame: up to Week 64

  8. PD: Changes from baseline in blood eosinophilic level after CM326 administration

    Changes from baseline in blood eosinophil level after CM326 administration

    Time frame: up to Week 64

  9. PD: Changes from baseline in eosinophilic level of nasal polyp biopsy tissue after CM326 administration

    Changes from baseline in eosinophil level of Nasal polyp biopsy tissue after CM326 administration

    Time frame: up to Week 64

  10. Efficacy: changes from baseline of nasal polyp score (NPS) in non-eosinophilic chronic rhinosinusitis with nasal polyps (CRSwNP)

    NPS score ranges from 0-8. (sum of 0-4 for each nasal passage scores), higher score means a worse outcome.

    Time frame: up to Week 64

07

Study locations

1 site
  • Beijing Tongren Hospital, CMU
    Beijing, Beijing, China
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2022 to primary completion in Mar 2024, 20 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 18, 2022
First posted
Apr 12, 2022
StartActual
Jul 11, 2022
Primary completionActual
Mar 29, 2024
CompletionActual
Mar 29, 2024
Last update
Nov 8, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 8, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05324137
Responsible party
Sponsor
First posted
Apr 12, 2022
Start date
Jul 11, 2022
Primary completion
Mar 29, 2024
Completion
Mar 29, 2024
Last update
Nov 8, 2024

Study contacts

Luo Zhang
principal investigator · Beijing Tong-Ren hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Ocankitug

Start the discussion